No­vo-backed start­up touts a PhII win for atri­al fib­ril­la­tion pro­gram

Den­mark-based biotech Ace­sion Phar­ma is tack­ling atri­al fib­ril­la­tion (AF), the most com­mon car­diac ar­rhyth­mia, with AP30663, its SK ion chan­nel in­hibitor that is be­ing de­vel­oped to bring the heart back to a nor­mal, healthy rhythm.

Ace­sion re­leased da­ta from its Phase II tri­al, con­duct­ed in hos­pi­tals in Hun­gary and Den­mark with 63 pa­tients who were hav­ing a cur­rent episode of AF. The pri­ma­ry end­point was the pro­por­tion of pa­tients with AF whose heart con­vert­ed back to a si­nus rhythm with­in 90 min­utes of the start of the AP30663 in­fu­sion. Over 50% of pa­tients on the high­est dose of the in­hibitor saw their hearts re­turn to a si­nus rhythm, while ze­ro on the place­bo did.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER